Back to Search Start Over

Molecular reductions in glucokinase activity increase counter-regulatory responses to hypoglycemia in mice and humans with diabetes

Authors :
Chakera, Ali J.
Hurst, Paul S.
Spyer, Gill
Ogunnowo-Bada, Emmanuel O.
Marsh, William J.
Riches, Christine H.
Yueh, Chen-Yu
Markkula, S. Pauliina
Dalley, Jeffrey W.
Cox, Roger D.
Macdonald, Ian A.
Amiel, Stephanie A.
MacLeod, Kenneth M.
Heisler, Lora K.
Hattersley, Andrew T.
Evans, Mark L.
Dalley, Jeffrey [0000-0002-2282-3660]
Evans, Mark [0000-0001-8122-8987]
Apollo - University of Cambridge Repository
Source :
Molecular Metabolism, Vol 17, Iss, Pp 17-27 (2018), Chakera, A J, Hurst, P S, Spyer, G, Ogunnowo-Bada, E O, Marsh, W J, Riches, C H, Yueh, C Y, Markkula, S P, Dalley, J W, Cox, R D, Macdonald, I A, Amiel, S A, MacLeod, K M, Heisler, L K, Hattersley, A T & Evans, M L 2018, ' Molecular reductions in glucokinase activity increase counter-regulatory responses to hypoglycemia in mice and humans with diabetes ', Molecular Metabolism . https://doi.org/10.1016/j.molmet.2018.08.001, Molecular Metabolism
Publication Year :
2018
Publisher :
Elsevier, 2018.

Abstract

Objective Appropriate glucose levels are essential for survival; thus, the detection and correction of low blood glucose is of paramount importance. Hypoglycemia prompts an integrated response involving reduction in insulin release and secretion of key counter-regulatory hormones glucagon and epinephrine that together promote endogenous glucose production to restore normoglycemia. However, specifically how this response is orchestrated remains to be fully clarified. The low affinity hexokinase glucokinase is found in glucose-sensing cells involved in glucose homeostasis including pancreatic β-cells and in certain brain areas. Here, we aimed to examine the role of glucokinase in triggering counter-regulatory hormonal responses to hypoglycemia, hypothesizing that reduced glucokinase activity would lead to increased and/or earlier triggering of responses. Methods Hyperinsulinemic glucose clamps were performed to examine counter-regulatory responses to controlled hypoglycemic challenges created in humans with monogenic diabetes resulting from heterozygous glucokinase mutations (GCK-MODY). To examine the relative importance of glucokinase in different sensing areas, we then examined responses to clamped hypoglycemia in mice with molecularly defined disruption of whole body and/or brain glucokinase. Results GCK-MODY patients displayed increased and earlier glucagon responses during hypoglycemia compared with a group of glycemia-matched patients with type 2 diabetes. Consistent with this, glucagon responses to hypoglycemia were also increased in I366F mice with mutated glucokinase and in streptozotocin-treated β-cell ablated diabetic I366F mice. Glucagon responses were normal in conditional brain glucokinase-knockout mice, suggesting that glucagon release during hypoglycemia is controlled by glucokinase-mediated glucose sensing outside the brain but not in β-cells. For epinephrine, we found increased responses in GCK-MODY patients, in β-cell ablated diabetic I366F mice and in conditional (nestin lineage) brain glucokinase-knockout mice, supporting a role for brain glucokinase in triggering epinephrine release. Conclusions Our data suggest that glucokinase in brain and other non β-cell peripheral hypoglycemia sensors is important in glucose homeostasis, allowing the body to detect and respond to a falling blood glucose.<br />Graphical abstract Image 1<br />HIGHLIGHTS • Reduced glucokinase (GCK) function increases hormonal responses to hypoglycemia. • β-cell GCK is responsible for insulin suppression as blood glucose levels fall. • Brain GCK-mediated hypoglycemia-sensing is involved in epinephrine release. • GCK-mediated glucagon secretion involves GCK that is not located in brain or β-cells.

Details

Language :
English
ISSN :
22128778
Volume :
17
Database :
OpenAIRE
Journal :
Molecular Metabolism
Accession number :
edsair.doi.dedup.....3790757ba77e77647b9ef28458dabd9a
Full Text :
https://doi.org/10.1016/j.molmet.2018.08.001